Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline

Psychopharmacology

Volumn 232, Issue 5, 2015, Pages 975-983

  Schassburger, Rachel L ^a   Levin, Melissa E ^a   Weaver, Matthew T ^b   Palmatier, Matthew I ^c   Caggiula, Anthony R ^a   Donny, Eric C ^a   Sved, Alan F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MERCYHURST COLLEGE   (United States)

^c EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

Nicotine; Rats; Reinforcement; Self administration; Varenicline

Indexed keywords

NICOTINE; VARENICLINE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SELF ADMINISTRATION; MALE; NONHUMAN; OPERANT BEHAVIORAL TEST; PRIMARY REINFORCING EFFECT; RAT; REINFORCEMENT; REINFORCEMENT ENHANCING EFFECT; SMOKING CESSATION; STIMULUS RESPONSE; VISUAL STIMULATION; ANIMAL; ASSOCIATION; DRUG EFFECTS; INSTRUMENTAL CONDITIONING; SPRAGUE DAWLEY RAT;

ANIMALS; BENZAZEPINES; CONDITIONING, OPERANT; CUES; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NICOTINE; NICOTINIC AGONISTS; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; SMOKING CESSATION; VARENICLINE;

EID: 84922810958     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3732-x     Document Type: Article

References (33)

1. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, Williams KE, Reeves KR (2008) Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomized open-label trial. Thorax 63:717-724. doi: 10.1136/thx.2007.090647
2. Brose LS, West R, Stapleton JA (2013) Comparison of the effectiveness of varenicline and combination nicotine replacement therapy for smoking cessation in clinical practice. Mayo Clin Proc 88:226-233. doi: 10.1016/j.mayocp.2012.11.013
3. Caggiula AR, Donny EC, Palmatier MI, Liu X, Chaudhri N, Sved AF (2009) The role of nicotine in smoking: a dual-reinforcement model. Nebr Symp Motiv 55:91-109
4. Cahill K, Stead LF, Lancaster T (2012) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 4:CD006103. doi: 10.1002/14651858.CD006103.pub6
5. Chaudhri N, Caggiula AR, Donny EC, Palmatier MI, Liu X, Sved AF (2006) Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology 184:353-366. doi: 10.1007/s00213-005-0178-1
6. Chaudhri N, Caggiula AR, Donny EC, Booth S, Gharib M, Craven L, Palmatier MI, Liu X, Sved AF (2007) Self-administered and noncontingent nicotine enhance reinforced operant responding in rats: impact of nicotine dose and reinforcement schedule. Psychopharmacology 190:353-362. doi: 10.1007/s00213-006-0454-8
7. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chamber LK, Rovetti CC, Schulz DW, Tingley FD III, O'Neill BT (2005) Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474-3477. doi: 10.1021/jm050069n
8. Corrigall WA, Coen KM (1989) Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology 99:473-478
9. Donny EC, Caggiula AR, Knopf S, Brown C (1995) Nicotine self-administration in rats. Psychopharmacology 122:390-394
10. Donny EC, Chaudhri N, Caggiula AR, Evans-Martin FF, Booth S, Gharib MA, Clements LA, Sved AF (2003) Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: implications for nicotine self-administration and reinforcement. Psychopharmacology 169:68-76. doi: 10.1007/s00213-003-1473-3
11. Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L, Gervais A, O'Loughlin J, Paradis G, Rinfret S, Pilote L (2008) Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 179:135-144. doi: 10.1503/cmaj.070256
12. Foulds J (2006) The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 60:571-576. doi: 10.1111/j.1368-5031.2006.00955.x
13. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, Varenicline Phase 3 Study G (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47-55. doi: 10.1001/jama.296.1.47
14. ∗- and alpha 7-nicotine acetylcholine receptors. Neuropharmacology 58:1054-1066. doi: 10.1016/j.neuropharm.2010.01.013
15. Harvey SC, Luetje CW (1996) Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits. J Neurosci 16:3798-3806
16. Harvey SC, Maddox FN, Luetje CW (1996) Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits. J Neurochem 67:1953-1959
17. Jackson KJ, Sanjakdar SS, Muldoon PP, McIntosh JM, Damaj MI (2013) The alpha3beta4∗nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the alpha 5 subunit in the mouse. Neuropharmacology 70:228-235. doi: 10.1016/j.neuropharm.2013.01.017
18. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, Varenicline Phase 3 Study G (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56-63. doi: 10.1001/jama.296.1.56
19. Levin ME, Weaver MT, Palmatier MI, Caggiula AR, Sved AF, Donny EC (2012) Varenicline dose dependently enhances responding for nonpharmacological reinforcers and attenuates the reinforcement-enhancing effects of nicotine. Nicotine Tob Res 14:299-305. doi: 10.1093/ntr/ntr213
20. Liu X, Palmatier MI, Caggiula AR, Donny EC, Sved AF (2007) Reinforcement enhancing effect of nicotine and its attenuation by nicotinic antagonists in rats. Psychopharmacology 194:463-473. doi: 10.1007/s00213-007-0863-3
21. Mihalak KB, Carroll FI, Luetje CW (2006) Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha 7 neuronal nicotinic receptors. Mol Pharmacol 70:801-805. doi: 10.1124/mol.106.025130
22. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR (2006) Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166:1561-1568. doi: 10.1001/archinte.166.15.1561
23. ∗-nAChR-mediated responses in mice in vivo. Nicotine Tob Res 14:711-719. doi: 10.1093/ntr/ntr284
24. Palmatier MI, Evans-Martin FF, Hoffman A, Caggiula AR, Chaudhri N, Donny EC, Liu X, Booth S, Gharib M, Craven L, Sved AF (2006) Dissociating the primary reinforcing and reinforcement-enhancing effects of nicotine using a rat self-administration paradigm with concurrently available drug and environmental reinforcers. Psychopharmacology 184:391-400. doi: 10.1007/s00213-005-0183-4
25. Palmatier MI, Liu X, Caggiula AR, Donny EC, Sved AF (2007) The role of nicotinic acetylcholine receptors in the primary reinforcing and reinforcement-enhancing effects of nicotine. Neuropsychopharmacology 32:1098-1108. doi: 10.1038/sj.npp.1301228
26. Palmatier MI, Liu X, Donny EC, Caggiula AR, Sved AF (2008) Metabotropic glutamate 5 receptor (mGluR5) antagonists decrease nicotine seeking, but do not affect the reinforcement enhancing effects of nicotine. Neuropsychopharmacology 33:2139-2147. doi: 10.1038/sj.npp.1301623
27. Paterson NE, Min W, Hackett A, Lowe D, Hanania T, Caldarone B, Ghavami A (2010) The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats. Prog Neuropsychopharmacol Biol Psychiatry 34:1455-1464. doi: 10.1016/j.pnpbp.2010.07.037
28. Picciotto MR, Mineur YS (2014) Molecules and circuits involved in nicotine addiction: the many faces of smoking. Neuropharmacology 76:545-553. doi: 10.1016/j.neuropharm.2013.04.028
29. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, Fuxe K, Changeux JP (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173-177. doi: 10.1038/34413
30. Richardson NR, Roberts DC (1996) Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66:1-11
31. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD III, Williams KE (2007) Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985-994. doi: 10.1016/j.neuropharm.2006.10.016
32. Sorge RE, Pierre VJ, Clarke PBS (2009) Facilitation of intravenous nicotine self-administration in rats by a motivationally neutral sensory stimulus. Psychopharmacology 207:191-200. doi: 10.1007/s00213-009-1647-8
33. Toll L, Zaveri NT, Polgar WE, Jiang F, Khroyan TV, Zhou W, Xie XS, Stauber GB, Costello MR, Leslie FM (2012) AT-1001: a high affinity and selective alpha3beta4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats. Neuropsychopharmacology 37:1367-1376. doi: 10.1038/npp.2011.322